Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Breast Neoplasms | 8 | 2024 | 144 | 4.380 |
Why?
|
Breast Neoplasms | 34 | 2024 | 20840 | 2.200 |
Why?
|
BRCA2 Protein | 9 | 2024 | 788 | 1.620 |
Why?
|
Receptor, erbB-2 | 10 | 2024 | 2483 | 1.460 |
Why?
|
BRCA1 Protein | 9 | 2024 | 1129 | 1.450 |
Why?
|
Paclitaxel | 3 | 2024 | 1699 | 1.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11587 | 0.840 |
Why?
|
Neoadjuvant Therapy | 12 | 2024 | 2789 | 0.800 |
Why?
|
Pyrazoles | 2 | 2024 | 1984 | 0.800 |
Why?
|
Nitriles | 2 | 2024 | 955 | 0.770 |
Why?
|
Ovarian Neoplasms | 4 | 2023 | 4808 | 0.720 |
Why?
|
Platinum | 1 | 2021 | 223 | 0.680 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13550 | 0.650 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2019 | 2122 | 0.560 |
Why?
|
Anthracyclines | 3 | 2020 | 282 | 0.540 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2017 | 325 | 0.530 |
Why?
|
Neutropenia | 1 | 2021 | 882 | 0.530 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 1515 | 0.490 |
Why?
|
Pyrimidines | 2 | 2024 | 2979 | 0.470 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 905 | 0.460 |
Why?
|
Medically Underserved Area | 1 | 2015 | 258 | 0.440 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1247 | 0.430 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2782 | 0.420 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 599 | 0.400 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 763 | 0.390 |
Why?
|
Immunoconjugates | 3 | 2023 | 865 | 0.370 |
Why?
|
Vulnerable Populations | 1 | 2015 | 694 | 0.350 |
Why?
|
Genetic Testing | 4 | 2024 | 3506 | 0.340 |
Why?
|
Female | 46 | 2024 | 386085 | 0.340 |
Why?
|
Troponin I | 2 | 2017 | 632 | 0.340 |
Why?
|
Camptothecin | 2 | 2023 | 578 | 0.320 |
Why?
|
Troponin T | 2 | 2017 | 766 | 0.320 |
Why?
|
Patient Selection | 3 | 2021 | 4239 | 0.320 |
Why?
|
Maytansine | 2 | 2019 | 86 | 0.290 |
Why?
|
Urban Population | 1 | 2015 | 2005 | 0.290 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2022 | 343 | 0.290 |
Why?
|
Humans | 56 | 2024 | 752411 | 0.280 |
Why?
|
Ovariectomy | 2 | 2020 | 610 | 0.270 |
Why?
|
Population Surveillance | 1 | 2015 | 2598 | 0.240 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9207 | 0.220 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8892 | 0.210 |
Why?
|
Lymphoma | 1 | 2011 | 1887 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5594 | 0.200 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2036 | 0.200 |
Why?
|
Mutation | 7 | 2022 | 29706 | 0.200 |
Why?
|
Weight Gain | 1 | 2011 | 2330 | 0.190 |
Why?
|
Survivors | 1 | 2011 | 2325 | 0.190 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11063 | 0.190 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 427 | 0.180 |
Why?
|
Omeprazole | 1 | 2021 | 113 | 0.180 |
Why?
|
Phthalazines | 1 | 2023 | 376 | 0.180 |
Why?
|
Neoplasms | 3 | 2019 | 21806 | 0.180 |
Why?
|
Receptors, Estrogen | 3 | 2022 | 2181 | 0.170 |
Why?
|
Lisinopril | 1 | 2019 | 54 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17647 | 0.170 |
Why?
|
Urogenital System | 1 | 2019 | 88 | 0.170 |
Why?
|
Piperazines | 2 | 2021 | 2487 | 0.170 |
Why?
|
Prognosis | 4 | 2023 | 29337 | 0.160 |
Why?
|
Treatment Outcome | 9 | 2024 | 64250 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2022 | 552 | 0.160 |
Why?
|
Germ-Line Mutation | 2 | 2024 | 1820 | 0.160 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 577 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 636 | 0.150 |
Why?
|
Carboplatin | 1 | 2021 | 788 | 0.150 |
Why?
|
Pyridines | 2 | 2021 | 2862 | 0.150 |
Why?
|
Middle Aged | 20 | 2023 | 217039 | 0.150 |
Why?
|
Cardiac Imaging Techniques | 1 | 2020 | 275 | 0.150 |
Why?
|
Brain | 1 | 2024 | 26659 | 0.140 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 871 | 0.140 |
Why?
|
Lymphedema | 1 | 2023 | 525 | 0.140 |
Why?
|
Genetic Counseling | 2 | 2023 | 616 | 0.140 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 292 | 0.140 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 672 | 0.130 |
Why?
|
Aged | 12 | 2021 | 166585 | 0.130 |
Why?
|
Adult | 16 | 2021 | 216927 | 0.130 |
Why?
|
District of Columbia | 1 | 2015 | 159 | 0.130 |
Why?
|
Central Nervous System | 1 | 2022 | 1330 | 0.130 |
Why?
|
Cell Adhesion Molecules | 1 | 2021 | 1599 | 0.120 |
Why?
|
Purines | 1 | 2018 | 600 | 0.120 |
Why?
|
Mastectomy | 1 | 2023 | 1822 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1051 | 0.120 |
Why?
|
Genetic Heterogeneity | 1 | 2018 | 716 | 0.120 |
Why?
|
Jews | 1 | 2016 | 359 | 0.120 |
Why?
|
Aminopyridines | 1 | 2018 | 560 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 2007 | 0.120 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4862 | 0.120 |
Why?
|
Retrospective Studies | 6 | 2023 | 79133 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1359 | 0.110 |
Why?
|
Breast | 1 | 2023 | 1975 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2024 | 3196 | 0.110 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2625 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 935 | 0.110 |
Why?
|
RNA | 1 | 2023 | 2700 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2018 | 854 | 0.110 |
Why?
|
Estrogens | 1 | 2019 | 1516 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5164 | 0.100 |
Why?
|
Time Factors | 5 | 2021 | 39846 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1180 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3755 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2023 | 3489 | 0.100 |
Why?
|
Obesity | 2 | 2023 | 12806 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6780 | 0.090 |
Why?
|
Carrier Proteins | 1 | 2024 | 4931 | 0.090 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3830 | 0.090 |
Why?
|
Germ Cells | 2 | 2024 | 632 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7235 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58299 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1096 | 0.080 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.080 |
Why?
|
Young Adult | 6 | 2020 | 57632 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10796 | 0.070 |
Why?
|
Heart Diseases | 1 | 2020 | 2790 | 0.070 |
Why?
|
DNA Repair | 1 | 2016 | 2022 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8443 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 813 | 0.060 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 1989 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 4950 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21157 | 0.060 |
Why?
|
Heart Failure | 1 | 2008 | 11729 | 0.060 |
Why?
|
Neuropilin-1 | 1 | 2024 | 90 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9613 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4377 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3599 | 0.060 |
Why?
|
Registries | 2 | 2020 | 8367 | 0.060 |
Why?
|
Pamphlets | 1 | 2023 | 71 | 0.050 |
Why?
|
Risk Assessment | 4 | 2024 | 23788 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18298 | 0.050 |
Why?
|
Risk Factors | 6 | 2023 | 73425 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 631 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 333 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9356 | 0.050 |
Why?
|
Axilla | 1 | 2023 | 612 | 0.050 |
Why?
|
Animals | 4 | 2024 | 166811 | 0.050 |
Why?
|
Body Weight | 1 | 2011 | 4605 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 53809 | 0.050 |
Why?
|
Genomics | 1 | 2016 | 5728 | 0.050 |
Why?
|
Stroke Volume | 3 | 2021 | 5451 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3678 | 0.040 |
Why?
|
Telephone | 1 | 2023 | 623 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15508 | 0.040 |
Why?
|
Administration, Intravaginal | 1 | 2019 | 149 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 664 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 720 | 0.040 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 510 | 0.040 |
Why?
|
Sex Factors | 1 | 2011 | 10457 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3600 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 453 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2023 | 1290 | 0.040 |
Why?
|
Logistic Models | 1 | 2011 | 13277 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 994 | 0.030 |
Why?
|
Quality of Life | 2 | 2022 | 13154 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2024 | 1341 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2022 | 1068 | 0.030 |
Why?
|
United States | 3 | 2020 | 71438 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1336 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3274 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1875 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1178 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15143 | 0.030 |
Why?
|
Atrophy | 1 | 2019 | 1606 | 0.030 |
Why?
|
Body Mass Index | 1 | 2011 | 12796 | 0.030 |
Why?
|
Gynecology | 1 | 2019 | 516 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14588 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15622 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 86766 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1506 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2019 | 2427 | 0.020 |
Why?
|
Qualitative Research | 1 | 2022 | 2888 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2407 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2796 | 0.020 |
Why?
|
Male | 3 | 2019 | 354908 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2172 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4110 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2192 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2556 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10172 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4601 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16737 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1775 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6501 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2131 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8420 | 0.020 |
Why?
|
Databases, Factual | 1 | 2020 | 7897 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9701 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 3935 | 0.010 |
Why?
|
Physicians | 1 | 2019 | 4551 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39077 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25539 | 0.010 |
Why?
|
Mice | 1 | 2024 | 80550 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 40980 | 0.010 |
Why?
|
Concepts
(190)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(58)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_